Microbix Biosystems Inc. (MBXBF)
USD 0.27
(10.2%)
USD 0.27
(10.2%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 35.65 Million CAD | 7.57% |
| 2022 | 33.14 Million CAD | 14.97% |
| 2021 | 28.82 Million CAD | 84.83% |
| 2020 | 15.59 Million CAD | -20.54% |
| 2019 | 19.62 Million CAD | 1.65% |
| 2018 | 19.31 Million CAD | -26.96% |
| 2017 | 26.43 Million CAD | 4.71% |
| 2016 | 25.24 Million CAD | 7.22% |
| 2015 | 23.54 Million CAD | 30.82% |
| 2014 | 17.99 Million CAD | 41.55% |
| 2013 | 12.71 Million CAD | -5.87% |
| 2012 | 13.5 Million CAD | -2.19% |
| 2011 | 13.81 Million CAD | -3.5% |
| 2010 | 14.31 Million CAD | 1.58% |
| 2009 | 14.08 Million CAD | -3.53% |
| 2008 | 14.6 Million CAD | 151.7% |
| 2007 | 5.8 Million CAD | 46.61% |
| 2006 | 3.95 Million CAD | 0.19% |
| 2005 | 3.94 Million CAD | 17.04% |
| 2004 | 3.37 Million CAD | 13.32% |
| 2003 | 2.97 Million CAD | 9.43% |
| 2002 | 2.72 Million CAD | -8.0% |
| 2001 | 2.95 Million CAD | 1.77% |
| 2000 | 2.9 Million CAD | 7.64% |
| 1999 | 2.7 Million CAD | -67.86% |
| 1998 | 8.4 Million CAD | -7.69% |
| 1997 | 9.1 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 37.73 Million CAD | -0.5% |
| 2024 Q2 | 37.92 Million CAD | 3.31% |
| 2024 Q1 | 36.7 Million CAD | 2.96% |
| 2023 FY | 35.65 Million CAD | 7.57% |
| 2023 Q2 | 33.19 Million CAD | 1.53% |
| 2023 Q3 | 34.29 Million CAD | 3.32% |
| 2023 Q1 | 32.69 Million CAD | -1.36% |
| 2023 Q4 | 35.65 Million CAD | 3.96% |
| 2022 FY | 33.14 Million CAD | 14.97% |
| 2022 Q2 | 32.94 Million CAD | 5.51% |
| 2022 Q3 | 33.29 Million CAD | 1.06% |
| 2022 Q1 | 31.22 Million CAD | 8.31% |
| 2022 Q4 | 33.14 Million CAD | -0.45% |
| 2021 Q1 | 16.28 Million CAD | 4.42% |
| 2021 Q2 | 17.95 Million CAD | 10.25% |
| 2021 Q3 | 25.86 Million CAD | 44.04% |
| 2021 FY | 28.82 Million CAD | 84.83% |
| 2021 Q4 | 28.82 Million CAD | 11.46% |
| 2020 Q1 | 19.75 Million CAD | 0.64% |
| 2020 FY | 15.59 Million CAD | -20.54% |
| 2020 Q3 | 20.48 Million CAD | -1.0% |
| 2020 Q4 | 15.59 Million CAD | -23.86% |
| 2020 Q2 | 20.69 Million CAD | 4.74% |
| 2019 FY | 19.62 Million CAD | 1.65% |
| 2019 Q1 | 19.92 Million CAD | 3.2% |
| 2019 Q2 | 20.3 Million CAD | 1.89% |
| 2019 Q3 | 20.32 Million CAD | 0.09% |
| 2019 Q4 | 19.62 Million CAD | -3.41% |
| 2018 FY | 19.31 Million CAD | -26.96% |
| 2018 Q2 | 26.86 Million CAD | -2.07% |
| 2018 Q3 | 28.17 Million CAD | 4.89% |
| 2018 Q4 | 19.31 Million CAD | -31.48% |
| 2018 Q1 | 27.43 Million CAD | 3.77% |
| 2017 Q4 | 26.43 Million CAD | 0.9% |
| 2017 Q2 | 25.84 Million CAD | 3.86% |
| 2017 FY | 26.43 Million CAD | 4.71% |
| 2017 Q1 | 24.88 Million CAD | -1.44% |
| 2017 Q3 | 26.2 Million CAD | 1.39% |
| 2016 Q2 | 24.15 Million CAD | 2.63% |
| 2016 Q4 | 25.24 Million CAD | 0.57% |
| 2016 Q1 | 23.53 Million CAD | -0.06% |
| 2016 Q3 | 25.1 Million CAD | 3.95% |
| 2016 FY | 25.24 Million CAD | 7.22% |
| 2015 FY | 23.54 Million CAD | 30.82% |
| 2015 Q1 | 18.84 Million CAD | 4.69% |
| 2015 Q4 | 23.54 Million CAD | 5.88% |
| 2015 Q2 | 22 Million CAD | 16.8% |
| 2015 Q3 | 22.23 Million CAD | 1.05% |
| 2014 Q4 | 17.99 Million CAD | 12.37% |
| 2014 Q1 | 12.44 Million CAD | -2.16% |
| 2014 FY | 17.99 Million CAD | 41.55% |
| 2014 Q3 | 16.01 Million CAD | 6.82% |
| 2014 Q2 | 14.99 Million CAD | 20.52% |
| 2013 Q2 | 13.01 Million CAD | 2.21% |
| 2013 Q4 | 12.71 Million CAD | -0.43% |
| 2013 Q3 | 12.77 Million CAD | -1.85% |
| 2013 Q1 | 12.73 Million CAD | -5.76% |
| 2013 FY | 12.71 Million CAD | -5.87% |
| 2012 FY | 13.5 Million CAD | -2.19% |
| 2012 Q4 | 13.5 Million CAD | 0.79% |
| 2012 Q3 | 13.4 Million CAD | -3.38% |
| 2012 Q2 | 13.87 Million CAD | 2.61% |
| 2012 Q1 | 13.51 Million CAD | -2.12% |
| 2011 Q2 | 16.99 Million CAD | 26.99% |
| 2011 FY | 13.81 Million CAD | -3.5% |
| 2011 Q4 | 13.81 Million CAD | -18.58% |
| 2011 Q3 | 16.96 Million CAD | -0.2% |
| 2011 Q1 | 13.38 Million CAD | -6.47% |
| 2010 Q3 | 13.51 Million CAD | -5.55% |
| 2010 Q2 | 14.31 Million CAD | 6.37% |
| 2010 Q1 | 13.45 Million CAD | -4.51% |
| 2010 Q4 | 14.31 Million CAD | 5.89% |
| 2010 FY | 14.31 Million CAD | 1.58% |
| 2009 FY | 14.08 Million CAD | -3.53% |
| 2009 Q3 | 13.93 Million CAD | -4.34% |
| 2009 Q4 | 14.08 Million CAD | 1.08% |
| 2009 Q1 | 14.1 Million CAD | -3.43% |
| 2009 Q2 | 14.56 Million CAD | 3.31% |
| 2008 Q2 | 11.54 Million CAD | -3.19% |
| 2008 Q1 | 11.92 Million CAD | 105.54% |
| 2008 FY | 14.6 Million CAD | 151.7% |
| 2008 Q4 | 14.6 Million CAD | 27.61% |
| 2008 Q3 | 11.44 Million CAD | -0.87% |
| 2007 Q4 | 5.8 Million CAD | -4.73% |
| 2007 FY | 5.8 Million CAD | 46.61% |
| 2007 Q1 | 3.8 Million CAD | -3.75% |
| 2007 Q2 | 4.02 Million CAD | 5.76% |
| 2007 Q3 | 6.09 Million CAD | 51.19% |
| 2006 Q4 | 3.95 Million CAD | -19.67% |
| 2006 FY | 3.95 Million CAD | 0.19% |
| 2006 Q2 | 4.97 Million CAD | 20.12% |
| 2006 Q1 | 4.13 Million CAD | 4.77% |
| 2006 Q3 | 4.92 Million CAD | -0.88% |
| 2005 Q1 | 3.5 Million CAD | 3.89% |
| 2005 Q2 | 3.7 Million CAD | 5.63% |
| 2005 FY | 3.94 Million CAD | 17.04% |
| 2005 Q4 | 3.94 Million CAD | 2.27% |
| 2005 Q3 | 3.86 Million CAD | 4.28% |
| 2004 Q3 | 3.07 Million CAD | 1.89% |
| 2004 Q2 | 3.01 Million CAD | 10.95% |
| 2004 Q4 | 3.37 Million CAD | 9.79% |
| 2004 FY | 3.37 Million CAD | 13.32% |
| 2004 Q1 | 2.71 Million CAD | -8.69% |
| 2003 Q4 | 2.97 Million CAD | 1.41% |
| 2003 Q2 | 2.87 Million CAD | -6.48% |
| 2003 Q1 | 3.07 Million CAD | 12.92% |
| 2003 FY | 2.97 Million CAD | 9.43% |
| 2003 Q3 | 2.93 Million CAD | 2.18% |
| 2002 Q3 | 2.7 Million CAD | 1.01% |
| 2002 FY | 2.72 Million CAD | -8.0% |
| 2002 Q2 | 2.67 Million CAD | -2.64% |
| 2002 Q1 | 2.74 Million CAD | -7.15% |
| 2002 Q4 | 2.72 Million CAD | 0.76% |
| 2001 Q1 | 3.01 Million CAD | 3.57% |
| 2001 FY | 2.95 Million CAD | 1.77% |
| 2001 Q3 | 3.12 Million CAD | 0.42% |
| 2001 Q4 | 2.95 Million CAD | -5.48% |
| 2001 Q2 | 3.11 Million CAD | 3.52% |
| 2000 FY | 2.9 Million CAD | 7.64% |
| 2000 Q1 | 2.6 Million CAD | -3.7% |
| 2000 Q4 | 2.9 Million CAD | 0.22% |
| 2000 Q3 | 2.9 Million CAD | 7.41% |
| 2000 Q2 | 2.7 Million CAD | 3.85% |
| 1999 Q2 | 6.6 Million CAD | -9.59% |
| 1999 Q4 | 2.7 Million CAD | -56.45% |
| 1999 Q3 | 6.2 Million CAD | -6.06% |
| 1999 Q1 | 7.3 Million CAD | -13.1% |
| 1999 FY | 2.7 Million CAD | -67.86% |
| 1998 Q4 | 8.4 Million CAD | 10.53% |
| 1998 FY | 8.4 Million CAD | -7.69% |
| 1998 Q3 | 7.6 Million CAD | -1.3% |
| 1998 Q2 | 7.7 Million CAD | -10.47% |
| 1998 Q1 | 8.6 Million CAD | -5.49% |
| 1997 Q2 | 2.8 Million CAD | 0.0% |
| 1997 Q3 | 9.1 Million CAD | 225.0% |
| 1997 Q1 | 2.8 Million CAD | 0.0% |
| 1997 FY | 9.1 Million CAD | 0.0% |
| 1997 Q4 | 9.1 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioxytran, Inc. | 137.63 Thousand USD | -25803.474% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 8.222% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -46594.376% |
| SQZ Biotechnologies Company | 107.18 Million USD | 66.738% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -2389.681% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -237.815% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 72.619% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -49168.326% |
| Marizyme, Inc. | 22.01 Million USD | -61.948% |
| Genus plc | 1.02 Billion USD | 96.535% |
| Pharming Group N.V. | 462.85 Million USD | 92.297% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -976.151% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -7044.336% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -5586.288% |
| ContraFect Corporation | 20.67 Million USD | -72.412% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -9228.93% |
| IMV Inc. | 31.33 Million USD | -13.785% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -759.933% |
| ONE Bio Corp. | 70.08 Million USD | 49.129% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 72.257% |
| Mesoblast Limited | 667.9 Million USD | 94.662% |
| MultiCell Technologies, Inc. | 126.22 USD | -28246631.104% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -1.347% |
| Genscript Biotech Corporation | 3.38 Billion USD | 98.947% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -4526.394% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -13545.68% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -393.825% |
| Biomind Labs Inc. | 73.81 Thousand USD | -48197.896% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -2360.793% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -18.784% |
| Skye Bioscience, Inc. | 11.94 Million USD | -198.591% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -2524.725% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -1198.204% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -9033.23% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1720.714% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -5086.0% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -3694.13% |
| EV Biologics, Inc. | 431.71 Thousand USD | -8158.482% |
| Q BioMed Inc. | 3.51 Million USD | -914.162% |
| GB Sciences, Inc. | 103.44 Thousand USD | -34366.681% |
| Alpha Cognition Inc. | 2.45 Million USD | -1353.938% |
| CSL Limited | 38.02 Billion USD | 99.906% |
| Agentix Corp. | 261.39 Thousand USD | -13539.677% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 92.012% |
| Enzolytics Inc. | 361.7 Million USD | 90.143% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 8.11 Million USD | -339.347% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1798.578% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1269.587% |
| argenx SE | 4.54 Billion USD | 99.215% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -27.587% |
| HST Global, Inc. | 1526.00 USD | -2336271.166% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 25.259% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -3508.726% |
| Halberd Corporation | 10.13 Thousand USD | -351820.087% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -5473.781% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -298.395% |
| Zenith Capital Corp. | 7410.00 USD | -481047.422% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -156403.332% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -10979.043% |
| AVAX Technologies, Inc. | 7.37 Million USD | -383.289% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -13541.138% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -3742.082% |
| Ember Therapeutics, Inc. | 184.00 USD | -19376543.478% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -57175.774% |
| Helix BioMedix, Inc. | 3.02 Million USD | -1078.579% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 32.348% |
| Kadimastem Ltd | 2.3 Million USD | -1447.387% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -144.865% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -62346.183% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -1543320.952% |
| LadRx Corporation | 2.3 Million USD | -1444.837% |
| Cell Source, Inc. | 195.17 Thousand USD | -18167.583% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -7319.104% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -9982.384% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -9982.384% |
| Affymax, Inc. | 7.44 Million USD | -379.014% |
| Mobile Lads Corp. | 52.00 USD | -68563407.692% |
| Itoco Inc. | 1.4 Million USD | -2446.514% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -37171.735% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -33534.928% |
| International Stem Cell Corporation | 5.39 Million USD | -561.466% |
| CytoDyn Inc. | 11.13 Million USD | -220.16% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -24837.067% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -199301.7% |
| Qrons Inc. | 420.00 USD | -8488715.238% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -9149.21% |
| SYBLEU INC | 330.46 Thousand USD | -10688.646% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -6357.477% |
| Rebus Holdings, Inc. | 5000.00 USD | -712960.48% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -8608.136% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -137.658% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -115.049% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -45030.41% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -4023.277% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -374.299% |
| Neutra Corp. | 2851.00 USD | -1250444.511% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -10.02% |
| PureTech Health plc | 693.97 Million USD | 94.862% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -341.737% |
| IXICO plc | 15.84 Million USD | -125.027% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -330.488% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 65.494% |
| CSL Limited | 38.02 Billion USD | 99.906% |
| Cellectis S.A. | 333.99 Million USD | 89.325% |